CCCC: the cash flow

MyFinsight

The latest financial statement is for the year ending 2025-12-31.

Cash Flow	2025-12-31
Net loss	-104,994
Stock-based compensation expense	19,099
Impairment loss on right-of-use asset	10,733
Depreciation and amortization	1,959
Reduction in carrying amount of right-of-use asset	6,434
Accretion of premium on marketable securities	2,742
Other	99
Accounts receivable	-701
Prepaid expenses and other current and long-term assets	-1,144
Accounts payable	-468
Accrued expenses and other current liabilities	-6,049
Operating lease liability	-5,774
Deferred revenue	-18,836
Net cash used in operating activities	-98,694
Proceeds from maturities of marketable securities	219,080
Purchase of marketable securities	227,074
Purchases of property and equipment	607
Net cash used in investing activities	-8,601
Proceeds from issuance of common stock-Underwritten Offering	116,870
Proceeds from issuance of common stock-At The Market Equity Program	9,341
Proceeds from issuance of common stock-Betta Pharma Stock Purchase Agreement	0
Proceeds from exercises of stock options	107
Payments for repurchase of common stock for tax withholding	193
Other	274
Net cash provided by financing activities	126,399
Net change in cash, cash equivalents and restricted cash	19,104
Cash, cash equivalents and restricted cash at beginning of period	58,942
Cash, cash equivalents and restricted cash at end of period	78,046

Unit: Thousand (K) dollars (except for numbers of shares and EPS).